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Summary 
• In the U.S., a rare disease is one that affects fewer than 200,000 patients. There are more 
than 7,000 rare diseases today but relatively few specific therapies for them, mainly be-
cause the manufacturers cannot recoup their drug development costs. 
• Orphan drug status allows sponsors to apply for incentives such as the Orphan Drug Tax 
Credit (ODTC), marketing exclusivity for seven years for the first orphan drug for a given 
rare disease, and an attractive drug-pricing scheme, amongst other benefits. 
• Orphan drug trials are generally single arm (no placebo arm), nonrandomized, and open 
label. Safety Phase 1 trials are not usually required, and Phases 2 and 3 can be combined 
when the patient population is very low. 
• Sponsors of an orphan drug can make use of expedited Food and Drug Administration 
(FDA) programs such as the Fast Track, Breakthrough Therapy, and Priority Review des-
ignations, as well as the Accelerated Approval pathway and unique grant funding 
opportunities, such as the Orphan Products Clinical Trials Grant program. 
• The FDA facilitates patient-focused drug development (PFDD) meetings, wherein they 
collect patient experience data from the patients, their family members, their caregivers, 
and disease foundations. These data can help the orphan drug developers for a given rare 
disease in determining clinical endpoints and the route of therapy administration for their 
clinical trials. 
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Topic Relevance by Timeline 
Summary 
● In the U.S., a rare disease is one that affects fewer than 200,000 patients. There are more 
than 7,000 rare diseases today but relatively few specific therapies for them, mainly be-
cause the manufacturers cannot recoup their drug development costs.  
● Orphan drug status allows sponsors to apply for incentives such as the Orphan Drug Tax 
Credit (ODTC), marketing exclusivity for seven years for the first orphan drug for a given 
rare disease, and an attractive drug-pricing scheme, amongst other benefits.  
● Orphan drug trials are generally single arm (no placebo arm), nonrandomized, and open 
label. Safety Phase 1 trials are not usually required, and Phases 2 and 3 can be combined 
when the patient population is very low.  
● Sponsors of an orphan drug can make use of expedited Food and Drug Administration  
(FDA) programs such as the Fast Track, Breakthrough Therapy, and Priority Review des-
ignations, as well as the Accelerated Approval pathway and unique grant funding 
opportunities, such as the Orphan Products Clinical Trials Grant program. 
● The FDA facilitates patient-focused drug development (PFDD) meetings, wherein they 
collect patient experience data from the patients, their family members, their caregivers, 
and disease foundations. These data can help the orphan drug developers for a given rare 
disease in determining clinical endpoints and the route of therapy administration for their 
clinical trials.  
Introduction 
During the 1990s, the pharmaceutical industry flourished due to the discoveries and introduction 
of small molecule “blockbuster” drugs, or drugs that bring pharmaceutical companies high annual 
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sales, into the market. When these drugs went off-patent in the 2000s, there was a rise in the 
generics industry. Since pharmaceutical companies struggle to come up with new drugs, and their 
previous discoveries are available as cheaper generics, many companies have started developing 
drugs for rare diseases, known as orphan drugs. These so-called “niche busters” constitute the 
fastest-growing area of drug development, with 14 orphan drugs approved between October and 
December 2017 (Pariser; Sharma et al.; Office of the Commissioner, “FDA-TRACK: Agency-
Wide Program Performance”). 
 
Orphan drugs are medicines or vaccines intended to treat, prevent, or diagnose a rare disease. In 
the United States, the FDA defines a rare disease as a disease or a condition that affects fewer than 
200,000 patients in the country. More than 7,000 rare diseases are estimated to exist today, affect-
ing approximately 6% to 8% of the world population (Melnikova; Mwamburi et al.).  
 
There is a scarcity of treatments for rare diseases, with fewer than one in ten rare disease patients 
receiving disease-specific treatment. Drug development for rare diseases is often limited by the 
large cost of investing in an original pharmaceutical agent with poor profit potential, given the 
small patient size per rare disease indication. Other obstacles include limited understanding of the 
disease, difficulty in identifying patients for trial recruitment, and trouble in identifying clinical 
centres with expertise in the disease to run the trials (Melnikova). 
 
Nonetheless, 39% of the novel drugs approved by the FDA Center for Drug Evaluation and 
Research (CDER) in 2017 were orphan drugs, mainly due to the provisions of the Orphan Drug 
Act of 1983 (“2017 New Drug Therapy Approvals”). An increase in this trend is expected in the 
future. It is therefore important to understand the critical regulations and the policy initiatives for 
orphan drugs that exist in our country, which are explained in this chapter. 
IND Process 
The first formal step for a sponsor who is ready to initiate clinical studies for a promising drug is 
to file for an Investigational New Drug (IND) application. A pre-IND meeting with the FDA is 
strongly advised. The IND application includes available information about the drug—data from 
preclinical, animal, and other studies indicating that it is reasonable to begin human trials (Center 
for Drug Evaluation and Research, “Investigational New Drug (IND) Application”) (see the chap-
ter on “FDA  Drug Regulation: Investigational New Drug Applications”).  
 
Early communication with the FDA is essential for the progress of a drug’s approval process. The 
CDER reviews most orphan drug applications, and the Office of Orphan Products Development 
(OOPD) promotes orphan drug development and provides grants for the same. It is advised to 
contact these organizations regularly (Institute of Medicine (US) Committee on Accelerating Rare 
Diseases Research and Orphan Product Development; West). 
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The ideal time to begin communicating with the FDA is prior to filing an IND application (Pariser). 
Timely review of IND submissions by the FDA, along with their feedback to sponsors, can result 
in greater efficiency of the drug development process. At the sponsor’s request, the FDA will, if 
possible, provide advice on specific IND matters (Center for Drug Evaluation and Research, “Best 
Practices for Communication Between IND Sponsors and FDA During Drug Development”). 
 
The officials whom the sponsors should contact are usually the regulatory project managers 
(RPMs) in the CDER review divisions or the Center for Biologics Evaluation and Research 
(CBER) review offices (collectively called “review division RPMs”). The review division RPMs 
and specific functional area RPMs are referred to as “FDA RPMs.”  
 
FDA RPMs communicate via written correspondence, email, fax, or telephone. They are the pri-
mary contacts for facilitating the timely resolution of technical, scientific, and regulatory 
questions, conflicts, or communication challenges between sponsors and the review teams. It is 
advised to communicate via a telephone call for any time-sensitive issue and later to follow up 
with a written communication (e.g., email, submission, or letter), so that there is a documentation 
of the decisions, agreements, or action terms that arose during the interaction (Center for Drug 
Evaluation and Research, “Best Practices for Communication Between IND Sponsors and FDA 
During Drug Development”). The FDA website lists the contact representatives and telephone 
numbers of different departments involved in different stages of the orphan drug development 
process. The Office of New Drugs (OND) and the CDER together provide guidance under the 
Rare Diseases Program. If the sponsor is unsure about whom to call or is not quite ready for clinical 
trials but has some questions, they can contact either the associate director for rare diseases or the 
regulatory scientist (Center for Drug Evaluation and Research, “Rare Diseases Program”). 
 
Formal meetings at critical points in the drug development process are useful for resolving ques-
tions and issues regarding drug development plans, the evidence required to demonstrate the 
effectiveness of the orphan drug, drug safety, clinical trial design, and product quality. These 
meetings help to minimize wasteful expenditures of time and resources, speeding up the drug 
development and evaluation process (Center for Drug Evaluation and Research, “Best Practices 
for Communication Between IND Sponsors and FDA During Drug Development”). 
Orphan Drug Designation 
The Orphan Drug Act (ODA) grants a special status to a drug or a biologic product that is intended 
to treat a rare condition or disease, upon the request of the sponsor. This status is referred to as 
“orphan designation” or “orphan status” (Office of the Commissioner, “Designating an Orphan 
Drug or Biologic”). 
 
Before the sponsor can apply for drug approval under the Orphan Drug Act and before the sponsors 
are eligible for incentives like the Orphan Products Grant, they must apply and receive the orphan 
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designation from the FDA (Institute of Medicine (US) Committee on Accelerating Rare Diseases 
Research and Orphan Product Development).  
 
The sponsor can submit the application for the designation anytime in the drug development pro-
cess before the submission of a marketing application for the drug of the same rare disease 
(“Electronic Code of Federal Regulations”). However, it is recommended that the application be 
done before the IND studies as it helps to design the trials when the requirements regarding clinical 
endpoints are known beforehand.  
 
The request for designation must be submitted to the OOPD with the information required in CFR 
316.20 and 316.21 (Office of the Commissioner, “Designating an Orphan Drug or Biologic”). 
Formal, preclinical study data are not required, since the FDA wants evidence of efficacy and the 
“scientific rationale” for the use of the drug. The applicant does not need to have animal toxicology 
data; only the results of efficacy studies conducted in an animal model for the human disease are 
needed (“Electronic Code of Federal Regulations”). The applicant may provide clinical data, ani-
mal studies, or in vitro data, but if sufficient information exists in published literature, that may 
suffice (Antos). 
 
The sponsor must submit documentation of the estimated prevalence of the disease or condition 
for which the drug is being developed, together with a list of the sources for the estimate, in order 
to prove that the drug would be administered in the U.S. to fewer than 200,000 patients. “Preva-
lence” is the number of persons in the U.S. who have been diagnosed with the disease at the time 
of the submission of the request for designation. If the drug is to treat a disease that affects a larger 
number of people, it may still be designated as an orphan if it is expected that the costs of research 
and development of the drug for a particular medical indication cannot be recovered by sales in 
the U.S. This is rare, and the sponsors must submit supporting data related to the cost of their 
development activities (“Electronic Code of Federal Regulations”). 
 
More than one sponsor may receive orphan drug designation of the same drug for the same rare 
disease or condition, but each sponsor seeking orphan drug designation must file a complete re-
quest for designation (“Electronic Code of Federal Regulations”). However, only the sponsor who 
receives the first FDA approval can receive orphan drug marketing exclusivity (discussed later). 
A manufacturer may obtain multiple orphan designations and approvals for different indications 
for the same product (Institute of Medicine (US) Committee on Accelerating Rare Diseases 
Research and Orphan Product Development). 
Regulation of Biologics  
Biologics are an important part of the orphan drug development, as certain rare diseases require 
therapies based on biologics, such as monoclonal antibodies, vaccines, and blood-based clotting 
factors, among others. Hence, it is important to understand the regulation of biologics by the FDA 
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(see the chapter on “Intellectual Property Protection for Biologics”). Generally, biologic drugs are 
held to the same standard of efficacy and safety as nonbiologic drugs. 
 
In 2003, the FDA transferred responsibility for review and approval of most therapeutic biologics 
from CBER to CDER. Nonetheless, the CBER continues to oversee vaccines, antitoxins, antiven-
ins, venoms, allergenic products, blood, and blood products. Depending on the category of the 
product being developed, the sponsor can approach the corresponding organization (Institute of 
Medicine (US) Committee on Accelerating Rare Diseases Research and Orphan Product Devel-
opment). 
 
Although the U.S. was the first country to introduce orphan drug legislation in 1983, Japan, 
Australia, and the EU followed suit soon after. However there are certain differences in how 
orphan drugs are handled in each of them. Sponsors are required to file for an orphan drug 
designation in all of these countries (Table 1). While there is no national plan for orphan drugs and 
rare diseases in the U.S., Japan, and Australia, there is one in place in the EU. All these countries 
allow independent marketing authorization, with Japan and the EU providing up to ten years of 
marketing exclusivity as opposed to seven years in the U.S. Australia does not allow marketing 
exclusivity to the manufacturers. In terms of pricing, Australia and Japan have a fixed pricing 
model, whereas different countries in the EU have different policies ranging from fixed pricing to 
free pricing and also reference-based pricing (Gammie et al.). 
New Drug Application/Biologics License Application 
Approval of all drugs must be based on substantial evidence of efficacy in preventing or treating 
the specific condition, along with evidence of safety for that use. The FDA expects sponsors to 
have an in-depth understanding of the disease and its natural history, which is not usually available 
for rare conditions. The FDA does not require that natural history studies be conducted, but when 
knowledge about the disease is insufficient to guide clinical development, a well-designed natural 
history study may help in designing an efficient drug development program (Center for Drug Eval-
uation and Research, “Rare Diseases: Common Issues in Drug Development Guidance for 
Industry”). 
 
A New Drug Application (NDA) or a Biologics License Application (BLA) is submitted for 
approval of the drug to be launched in the market, and it contains the results from the human 
clinical trials. An NDA is for the market approval of small molecule drugs, whereas a BLA is for 
the approval of biologics. The required substantial evidence of efficacy and safety is based on the 
results of two or more (for common diseases) and sometimes only one (for rare diseases) adequate 
and well-controlled (A&WC) investigations designed and conducted such that they are able to 
“distinguish the effect of a drug from other influences, such as spontaneous change in the course 
of a disease, placebo effect, or biased observation” (21 CFR 314.126, 2018).  
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Table 1. Orphan Drug Benefits in Some Other Major Countries 
(Adapted from (Gammie et al.)). 
 
Country Orphan Drug 
Designation 
Marketing 
Exclusivity 
Financial 
Incentives 
Nonfinancial 
Incentives 
Pricing 
Australia Yes No Fee reduction 
for marketing 
authorization 
approval 
Pre-licensing 
access, 
regulatory 
assistance 
Fixed 
Canada No No Tax incentives, 
fee reduction 
for marketing 
authorization 
Pre-licensing 
access, 
scientific 
advice, 
protocol 
assistance, 
regulatory 
assistance 
Reference 
pricing 
Japan Yes 10 years Financial 
subsidies, tax 
credits, user 
fee waivers 
Priority 
review, fast 
track approval, 
free protocol 
assistance 
Fixed = cost + 
10% 
EU5 
(France, 
Germany, 
Italy, Spain, 
U.K.)  
Yes 10 years Reduced 
rebates in 
Spain and tax 
exemptions in 
France 
Pre-licensing 
access in all 
EU5 countries, 
protocol 
assistance and 
scientific 
advice in 
France and 
Italy 
Free pricing 
in Germany, 
reference 
pricing in 
Italy, fixed 
pricing in 
Spain and the 
U.K, and 
price 
negotiations 
in France 
 
Rare disease interventional trials differ from those in non-rare conditions, with notable differences 
in enrollment, design, blinding, and randomization. For clinical trials of rare diseases, there is 
frequently no requirement for a placebo arm and a safety Phase 1 study in healthy volunteers. For 
diseases with a very small population, the FDA accepts trials where Phase 2 and Phase 3 are con-
densed together to test for efficacy as well as safety in the patients. A study done in 2014 shows 
that the majority of the rare disease clinical trials between 2006 and 2012 enrolled fewer 
participants, were more likely to be single arm, nonrandomized, and open label when compared to 
the non-rare disease clinical trials (Bell and Tudur Smith). 
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Orphan Products Clinical Trials Grants Program and 
Other Resources 
Originally called the Orphan Products Grants, these grants are provided by the FDA for clinical 
studies on safety and/or effectiveness that will either result in or substantially contribute to market 
approval of these products for rare diseases. These grants are funded by the FDA’s Office of 
Orphan Products Development (OOPD). The application for these grants must include a clear doc-
umentation of the estimated prevalence of the orphan disease/condition—showing that it is 
intended to treat a disease with fewer than 200,000 patients in the U.S.—and an explanation of 
how the proposed clinical study will provide the essential data needed for product development. It 
is not necessary for a drug or biologic product to hold orphan drug designation to be eligible for 
the grant program.  
 
The OOPD receives about 100 applications per year and has funded over 700 studies so far. In 
general, the OOPD grant funding lasts between three and four years. Phase 1 studies are eligible 
for up to $250,000 per year for up to three years. Phase 2 and 3 studies are eligible for up to 
$500,000 per year for up to four years (Office of the Commissioner, “Orphan Products Clinical 
Trials Grants Program”). 
 
The National Organization for Rare Disorders’ (NORD) Research Grant Program provides seed 
grants to academic scientists in the U.S. or outside, for translational or clinical studies related to 
the development of potential new diagnostics or treatments for rare diseases. Out of each grant 
awarded between $30,000 and $50,000, NORD uses $5,000 to cover the administrative expenses 
and direct costs of initiating a request for proposals (RFP). A search for researchers who have 
published journal articles about a specific disease in the last two to five years is conducted in order 
to reach the most expert scientists. Each research proposal is reviewed by NORD’s Medical Ad-
visory Committee, which recommends funding for the highest-scored proposals. After the grant is 
awarded, NORD monitors the progress of the research, processing biannual reports to NORD’s 
Medical Advisory Committee (“Research Grant Program”). 
 
The NIH’s National Center for Advancing Translational Sciences (NCATS) collaborates with the 
National Human Genome Research Institute (NHGRI) to support the Genetic and Rare Diseases 
Information Center (GARD). GARD was established to help the researchers working in this space 
by providing fundamental information and resources to formalize their study protocols. GARD 
information specialists can provide custom literature searches, GARD’s rare disease list, and a 
contact network of advocacy organization. These organizations may collaborate in the research 
and assist the sponsors in the recruitment of a team. They can also direct the researchers to NIH 
programs that support rare disease research, such as the Rare Diseases Clinical Research Network 
(RDCRN), Therapeutics for Rare and Neglected Diseases (TRND), and the Bridging Interven-
tional Development Gaps program (BrIDGs) (NCATS NIH). These programs are funded by the 
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NCATS to assist researchers with developing clinical trials or therapeutic agents. There are 
foundations for specific diseases listed on the GARD website that provide funding resources to 
researchers working on that particular condition. For example, the Prader-Willi Syndrome 
Association (PWSA) offers one- to two-year grants for a maximum of $100,000 for projects aimed 
at discovering and developing treatments, cures, and technologies benefiting those with Prader-
Willi syndrome (Genetic and Rare Diseases Information Center (GARD) and National Center for 
Advancing Transnational Sciences). 
Key Financial Incentives of Orphan Drug Designation 
Figure 1. Financial Incentives of Orphan Drug Designation.  
 
 
Orphan drug tax credit (ODTC) 
The developers of an orphan drug get a tax credit for 50% of qualified clinical trials cost plus seven 
years of market exclusivity. Since the credit’s inception in 1983, the FDA has approved more than 
500 such drugs, as opposed to only 10 prior to it. However, congressional Republicans proposed 
to repeal the orphan drug tax credit as part of a U.S. tax reform package (Cunningham), and the 
senate bill proposed to decrease it to 27.5% (Dickey). The tax credit has been a huge financial 
incentive for the orphan drug manufacturers, and the credit’s uncertain future spurred a large-scale 
“Save Orphan Drugs” movement against the repealment of the tax credit. The National Organiza-
tion for Rare Disorders (NORD) strongly advocated that the ODTC be strengthened, or at the very 
least maintained at 27.5% and not reduced any further(Jensen). However, as of this writing, the 
ODTC has been reduced to 25% (Wechsler). 
 
Prescription Drug User Fee Act (PDUFA) exemption 
The FDA has the authority to assess and collect user fees for certain drug and biologics license 
applications. Pharmaceutical companies pay fees for certain new human drug applications, biolog-
ics applications, and supplements submitted to the agency for review. This fee is around $2.2 
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million in value (Antos). Review of an application by the FDA cannot begin until the fee has been 
submitted.  
 
A human drug NDA/BLA application for an orphan drug is not subject to an application fee unless 
the human drug application includes an indication other than the rare condition. Form FDA 3397, 
the PDUFA user fee cover sheet, is designed to provide the minimum necessary information to 
determine whether a fee is required for review of an application (Center for Drug Evaluation and 
Research, “PDUFA User Fee Cover Sheet”). If an application qualifies for an orphan exemption, 
the applicant does not need to send the FDA a written request. The applicant should simply notify 
the FDA that they are claiming the orphan exemption when they complete and submit FDA Form 
3397. This form should be included with the application or supplement, and a brief statement 
claiming the orphan exception should be included in the cover letter (Center for Drug Evaluation 
and Research, “User Fee Waivers, Reductions, and Refunds for Drug and Biological Products”). 
 
Marketing exclusivity and free pricing  
Marketing exclusivity is given to orphan drug developers in order to provide several years to 
recover their drug development costs. The FDA’s orphan drug exclusivity (ODE) period runs for 
seven years from the time of approval of the NDA or BLA. During the marketing exclusivity 
period, the FDA cannot approve a generic drug abbreviated new drug application (ANDA) for the 
same drug or brand name drug (full NDA or BLA application) for the same rare disease indication 
(Seoane-Vazquez et al.; Lal). However, the same drug can receive approval for a different disease 
indication, and no limits are currently put in place on the number of drugs that may be selected for 
the same rare disease profile. 
 
Pricing of the orphan drugs is unique in that it is designed to retrieve the costs of R&D from a 
small number of patients, compared to the pricing model of other drugs, where pricing is often 
based on the capacity of the customer to pay.  Given this, the marketing exclusivity, and the lack 
of therapeutic alternatives, orphan drugs are relatively expensive. Spark Therapeutics’ Luxturna 
costs $850,000 for a one-time gene therapy treatment for a  rare, inherited retinal disease that can 
lead to blindness (Tirrell). One of the reasons for this is that patients with rare diseases often have 
a high willingness to pay, given the limited therapeutic alternatives and the life-threatening or 
chronically debilitating nature of many rare diseases. Pricing is also influenced by the change in 
quality of life in a more cost-effective approach. In other words, a drug that could provide a cure 
will be priced higher than a drug that provides just symptomatic relief or treatment. Therefore, 
third-party payers (insurance companies) are generally forced to pay the manufacturer’s high price. 
In addition, the free pricing scheme in the U.S. allows the manufacturer to set the price at their 
discretion. In comparison, in different European countries, pricing is controlled by a single-payer 
system and cost referencing with other nations (Gammie et al.). 
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Eligibility for Expedited Approval Processes 
Figure 2. Four Successful Rapid Approval Processes Allocated by the FDA.  
 
 
 
Out of the CDER new molecular entity (NME) approvals between 2008 and 2016, a significantly 
higher number of orphan drugs used expedited clinical development programs compared to the 
non-rare disease drugs (Moscicki). If the drug is eligible, the sponsor can make use of any of the 
four rapid-approval processes allocated by the FDA (Figure 2): 
 
Fast Track (designation) 
This designation facilitates the development and speeds up the FDA review process of drugs that 
would treat serious conditions and fill an unmet medical need. To be eligible as a drug that treats 
a serious condition, the drug must positively impact such factors as survival, day-to-day function-
ing, or the likelihood that the condition, if left untreated, will progress from a less severe condition 
to a more serious one. Filling an unmet need means that no current therapy is available for the 
condition or that the proposed therapy is potentially better than available therapies (see the chapter 
“Identifying Unmet Needs: Problems that Need Solutions”). If there are available therapies, a Fast 
Track drug must show some advantage over available therapy, such as evidence of superior 
effectiveness, improved effectiveness on serious outcomes, or lesser side effects (Office of the 
Commissioner, “Fast Track”). 
 
The sponsor can initiate the request for Fast Track designation anytime during the drug 
development process. The FDA will review and make a decision within 60 days from the request. 
The type of data required are usually preliminary nonclinical and mechanistic or clinical data 
(Krulewitz). Ideally, the sponsor should submit the application no later than the pre-BLA or the 
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pre-NDA meeting (Center for Drug Evaluation and Research, “Expedited Programs for Serious 
Conditions––Drugs and Biologics”). 
 
The benefits of Fast Track designation include more frequent meetings and written communication 
with the FDA, and rolling review. Rolling review refers to the ability of the FDA to begin review 
of the BLA or NDA as sections are completed, rather than waiting for the finalized NDA or BLA 
to begin the review (Office of the Commissioner, “Fast Track”). 
 
Breakthrough Therapy (designation) 
This program is similar to the Fast Track program in providing quick review of drugs that are 
intended to treat a serious condition and are better than any available therapy. The most important 
difference between the two is the type of data that needs to be submitted to get a Breakthrough 
Therapy designation, which is preliminary clinical evidence indicating that the drug may demon-
strate substantial improvement over available therapy on (a) clinically significant endpoint(s). 
Substantial improvement is judged on the basis of the magnitude of the treatment effects and the 
importance of the observed clinical outcome. A clinically significant endpoint is one that measures 
an effect on irreversible morbidity or mortality (IMM) or on symptoms that represent serious 
consequences of the disease. It can also refer to findings that suggest an effect on IMM or serious 
symptoms (Office of the Commissioner, “Breakthrough Therapy”). 
 
Ideally, a Breakthrough Therapy designation request should be received by the FDA from the 
sponsor no later than the end-of-Phase-2 meetings. The FDA responds to the request within 60 
days of the receipt of request (Office of the Commissioner, “Breakthrough Therapy”). 
 
Along with the benefits of a Fast Track designation, Breakthrough Therapy drug sponsors are also 
given intensive guidance on an efficient drug development program and have the involvement of 
FDA senior managers. It is fairly common  for a drug on the fast track to be granted Breakthrough 
Therapy designation during the drug development process (Krulewitz; Office of the Commis-
sioner, “Breakthrough Therapy”). 
 
Accelerated Approval (approval pathway) 
Instituted in 1992 by the FDA, Accelerated Approval regulations allow drugs for serious 
conditions that fill an unmet medical need to be approved based on a surrogate endpoint. This 
endpoint should be a marker like a laboratory measure or a radiographic image, but is not itself a 
clinical benefit. Studies demonstrating this must be A&WC (Office of the Commissioner, “Accel-
erated Approval”). 
 
The sponsor should discuss the possibility of accelerated approval with the review division during 
development, supporting, for example, the use of the planned endpoint as a basis for approval and 
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discussing the confirmatory trials, which should usually be already underway at the time of ap-
proval (Center for Drug Evaluation and Research, “Expedited Programs for Serious Conditions––
Drugs and Biologics”). 
 
It is important to note here that the sponsor is required to conduct additional clinical trials after the 
approval (Phase 4 or post-market surveillance) of the drug to confirm the clinical benefit. Until the 
clinical benefit is confirmed, the label mentions that the use of the drug has not shown clinical 
benefit yet. Moreover, failure to do these Phase 4 clinical trials can result in removal of the drug 
from the market (Krulewitz). 
 
Priority Review (designation) 
In 1992, under the PDUFA, the FDA agreed to a Priority Review designation of any drug for which 
the agency would take action within six months to review the application, as opposed to ten months 
otherwise. The sponsor must submit an application (original or efficacy supplement) for a drug 
that treats a serious condition and, if approved, would provide a significant improvement in safety 
or effectiveness. Other eligibility criteria can be seen on the FDA website (Office of the Commis-
sioner, “Priority Review”). 
 
The sponsor must submit the request for the original BLA or NDA, or the efficacy supplement. 
The FDA responds within 60 days after the submission of request (Center for Drug Evaluation and 
Research, “Expedited Programs for Serious Conditions––Drugs and Biologics”). 
Seeking Expert Guidance  
Partnering with clinical and/or regulatory experts who have relevant experience could help guide 
the developers of an orphan drug to approval, potentially saving the developer significant resources 
in time and money (West). Candidate partners could be large pharmaceutical companies and cer-
tain nonprofit organizations and foundations. The most important areas to look for when 
considering a partnership with a pharmaceutical company are the partnering company’s 
commitment to the rare disease community, their ability to find innovative methods for patient 
group identification, their ability to navigate patient access to rare disease therapies, and their 
intention to give sustained support to the patients and their caregivers (Ascher et al.). 
 
Patient experience data (PED) are collected by diverse stakeholders (including patients, family 
members, caregivers, disease research foundations, researchers, and drug manufacturers) and are 
intended to provide information about a patient’s experience with a disease, including its impact 
and the patient’s preference for or against its treatment (“Public Workshop on Patient-Focused 
Drug Development: Developing and Submitting Proposed Draft Guidance Relating to Patient 
Experience Data”). Patient-focused drug development (PFDD) meetings are one of the helpful 
community engagement mechanisms designed by the FDA. PFDD is a systematic approach to help 
ensure that patients’ experiences, perspectives, needs, and priorities are captured and meaningfully 
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incorporated into drug development and evaluation. Although pharmaceutical companies are not 
involved in such meetings, the makers of orphan drugs can benefit significantly by reviewing the 
PED collected in such meetings. The 21st Century Cures Act of 2016 states that the FDA will 
conduct public workshops to draft guidance documents related to the PFDD meetings (FDA Plan 
for Issuance of Patient-Focused Drug Development Guidance). The most recent workshop was 
held on March 19, 2018, and the meeting slides and recordings are available online (Office of the 
Commissioner, “Public Workshop on Patient-Focused Drug Development: Developing and 
Submitting Proposed Draft Guidance Relating to Patient Experience Data”). 
Conclusion 
Orphan drugs target rare diseases that affect fewer than 200,000 patients in the U.S. The Orphan 
Drug Act was signed in 1983 and provided for various incentives for orphan drug development. 
Since then, the orphan drug industry has been growing at a very fast rate. Researchers working on 
orphan drugs must learn about these incentives and others that are offered by nonprofit 
organizations and groups. Patients and their caregivers are coming together to generate data that 
will help drug developers come up with new therapies for rare diseases. Although the drug 
approval process remains the same for all drugs, exceptions are made in cases of rare disease drugs. 
Not only do orphan drug trials require smaller number of patient populations and condensed phase 
studies but they also are eligible for tax credits and grants. Additionally, the U.S. free pricing of 
drugs and patients’ higher willingness to pay for rare disease therapies make orphan drug devel-
opment less expensive and allow for recovering the R&D costs during the seven years of marketing 
exclusivity. Pharmaceutical companies increasingly want to invest in these therapies and look for 
ways to partner with researchers and small biotech startups.  
Practical Guides/Worksheets 
FDA Orphan Drug Designation Checklist: For Sponsor Seeking Orphan 
Designation  
(“CFR—Code of Federal Regulations Title 21”) 
 
This checklist is to make sure that the sponsor has submitted all the required information to the 
FDA for obtaining the orphan drug designation for their proposed drug. 
1. Have you included the description of the rare disease/condition for which the drug is being or 
will be investigated, the proposed use of the drug, and the reasons why such therapy is needed? 
Yes   No 
2. Have you discussed in the request, the scientific rationale to establish a medically plausible 
basis for the use of the drug for the rare disease? 
Yes   No 
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3. Have you included all copies of pertinent unpublished and published papers that provide 
evidence  of the medical plausibility of the treatment? 
Yes   N/A 
4. Is the number of people affected with the disease or condition for which the drug is being 
developed is fewer than 200,000 persons in the U.S.? 
Yes   No  
OR 
Is there no reasonable expectation that the sales of the drug will be sufficient to offset the costs 
of developing the drug for the U.S. market and the costs of making the drug available in the 
United States? 
Yes   No 
5. Is the estimated prevalence of the disease together with a list of sources (including dates of 
information provided and literature citations) included in the documentation? 
Yes   No 
6. If the drug is a vaccine or a drug intended for diagnosis or prevention of a rare 
disease/condition, is the estimated number of people to whom the drug will be administered 
annually listed? 
Yes   N/A 
7. If your drug is the same drug as an already approved drug and seeks orphan drug designation 
for the same rare disease, have you justified that the proposed variation may be clinically 
superior to the first drug? 
Yes   N/A 
Resources 
1. Orphan Disease Center 
a. The Orphan Disease Center (ODC) at Penn, led by Dr. Jim Wilson, provides a unique 
set of programs that add value to every drug development stage, from building the 
initial knowledge base to enabling therapeutic development. Through their grants, the 
Programs of Excellence, international patient registries, Jump Start programs, and a 
number of new initiatives, the ODC seeks to drive therapeutic development for rare 
diseases. The ODC offers 50+ grant opportunities in 30+ diseases annually to 
researchers. Key functions of the ODC include—but are not limited to—uniting 
investigators and clinicians within Penn, CHOP, and internationally who are 
committed to treating and curing orphan conditions, creating resources for the rare 
disease community, and providing means for pharmaceutical and biotech companies 
to partner with researchers. The ODC’s Million Dollar Bike Ride pilot grant program 
opened in the summer of 2018.  
b. http://www.orphandiseasecenter.med.upenn.edu/. 
2. Orphan Products Natural History Grants Program  
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a. The Orphan Products Natural History Grants Program by the OOPD supports studies 
that advance rare disease medical product development. The searchable database for 
these grants will be available soon.  
b. https://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/Orp
hanProductsNaturalHistoryGrantsProgram/default.htm. 
3. Genetic and Rare Diseases Information Center (GARD)  
a. The detailed guides for researchers on “Finding Research Participants” and “Where to 
find statistics for Rare Diseases” will be available soon on the NIH’s GARD 
webpage.  
b. https://rarediseases.info.nih.gov/about-gard/pages/23/about-gard. 
4. Search database of Orphan Drug designations and approvals 
a. If a product receives orphan drug designation, certain information about the orphan 
designated product (sponsor’s name, address, and contact information, as well as the 
name of the drug, orphan designated use, and the date of designation) is updated 
monthly on the searchable database on the FDA’s website. 
b. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/. 
5. FDA Track Updates 
a. Sponsors could subscribe to the FDA track updates to keep track of drugs being 
accepted for the expedited programs.  
b. https://www.fda.gov/AboutFDA/Transparency/track/default.htm. 
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